Literature DB >> 3521714

A reappraisal of the effects of iron and desferrioxamine on the growth of Plasmodium falciparum 'in vitro': the unimportance of serum iron.

T E Peto, J L Thompson.   

Abstract

It has been suggested that P. falciparum takes up iron from serum and that desferrioxamine, an iron chelating agent, inhibits parasite growth. We have now shown, however, that when all the iron is transferrin bound, P. falciparum, in culture, takes up less than 7 pmol Fe/10(9) parasites/24 h and that incorporation is increased only in the presence of a high molecular weight iron complex not naturally found in serum. Furthermore, removal of iron serum did not reduce parasite growth, and addition of excess iron was inhibitory. Desferrioxamine inhibited growth, but this inhibition was reduced under conditions in which the transfer of iron from transferrin to desferrioxamine was accelerated. We conclude that P. falciparum does not directly utilize serum iron and that desferrioxamine does not inhibit the parasite by interfering with the supply of iron from the incubation medium. The results are relevant to clinical data which suggest that added nutritional iron enhances the host susceptibility to malaria.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3521714     DOI: 10.1111/j.1365-2141.1986.tb05550.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  11 in total

1.  Chloroquine inhibits the intracellular multiplication of Legionella pneumophila by limiting the availability of iron. A potential new mechanism for the therapeutic effect of chloroquine against intracellular pathogens.

Authors:  T F Byrd; M A Horwitz
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

Review 2.  Iron and infection.

Authors:  C Hershko; T E Peto; D J Weatherall
Journal:  Br Med J (Clin Res Ed)       Date:  1988-03-05

3.  In vitro antimalarial activity of a new organometallic analog, ferrocene-chloroquine.

Authors:  O Domarle; G Blampain; H Agnaniet; T Nzadiyabi; J Lebibi; J Brocard; L Maciejewski; C Biot; A J Georges; P Millet
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

4.  Effects of synthetic siderophores on proliferation of Plasmodium falciparum in infected human erythrocytes.

Authors:  Andrea Rotheneder; Gernot Fritsche; Lothar Heinisch; Ute Möllmann; Susanne Heggemann; Clara Larcher; Günter Weiss
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

5.  Deferoxamine and eflornithine (DL-alpha-difluoromethylornithine) in a rat model of Pneumocystis carinii pneumonia.

Authors:  A B Clarkson; M Sarić; R W Grady
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

6.  Clinically achievable plasma deferoxamine concentrations are therapeutic in a rat model of Pneumocystis carinii pneumonia.

Authors:  S Merali; K Chin; L Del Angel; R W Grady; M Armstrong; A B Clarkson
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

7.  Reversed siderophores act as antimalarial agents.

Authors:  A Shanzer; J Libman; S D Lytton; H Glickstein; Z I Cabantchik
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-01       Impact factor: 11.205

8.  The antimalarial action of desferal involves a direct access route to erythrocytic (Plasmodium falciparum) parasites.

Authors:  M Loyevsky; S D Lytton; B Mester; J Libman; A Shanzer; Z I Cabantchik
Journal:  J Clin Invest       Date:  1993-01       Impact factor: 14.808

9.  Inhibitory effect of novel iron chelator, 1-(N-acetyl-6-aminohexyl)-3-hydroxy-2-methylpyridin-4-one (CM1) and green tea extract on growth of Plasmodium falciparum.

Authors:  Phitsinee Thipubon; Chairat Uthaipibull; Sumalee Kamchonwongpaisan; Wachiraporn Tipsuwan; Somdet Srichairatanakool
Journal:  Malar J       Date:  2015-09-30       Impact factor: 2.979

10.  Deferoxamine inhibition of malaria is independent of host iron status.

Authors:  C Hershko; T E Peto
Journal:  J Exp Med       Date:  1988-07-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.